Our History
We have a proven track record of efficient and consistent achievement.
Our company was founded in 2017 with a vision of harnessing novel biology to develop therapeutics with a transformational, global impact on patients’ lives. We have made rapid progress toward that goal and pride ourselves on accurately projecting—and delivering—important milestones. Now we will continue on this path as part of Novo Nordisk.
SYMMETRY Phase 2b Week 96 Readout
We announced preliminary topline results demonstrating statistically significant reversal of cirrhosis in patients with compensated cirrhosis (F4) following 96 weeks of treatment with EFX
Acquisition by Novo Nordisk
We announced that we have entered into a definitive agreement to be acquired by Novo Nordisk A/S, adding EFX to the company’s portfolio of treatment options across the stages of MASH, embodying Novo Nordisk’s commitment to pursue leadership in diabetes, obesity, and their associated comorbidities
HARMONY Phase 2b week 96 study readout reported topline week 96 data showing statistically significant histological improvements, demonstrating ≥1- and ≥2-stage fibrosis improvement without worsening of MASH at both 50mg and 28mg doses of EFX
Public follow-on offering with gross proceeds of approximately $366.9M
Public offering of $334.8M in net proceeds raised
SYMMETRY Phase 2b Expansion Cohort D readout showed safety and tolerability endpoints were met, and that adding EFX to GLP-1 therapy significantly improved noninvasive markers of MASH, offering benefit over GLP-1 therapy alone
SYMMETRY Phase 2b week 36 readout showed EFX treatment in F4 patients had a trend on fibrosis improvement, which was not statistically significant, and statistically significant results for MASH resolution, markers of liver injury and fibrosis, insulin sensitization and lipoproteins
Phase 3 SYMMETRY program initiated and dosed the first patients in two parallel, randomized, placebo-controlled Phase 3 trials: SYNCHRONY Histology evaluating the efficacy and safety of EFX in patients with biopsy-confirmed pre-cirrhotic MASH, and SYNCHRONY Real-World assessing safety and tolerability of EFX in patients with noninvasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD)
HARMONY Phase 2b study readout showed statistical significance on both primary and secondary histology endpoints after 24 weeks in pre-cirrhotic (F2-F3) MASH
Upsized public follow-on offering with gross proceeds of approximately $230M
FDA breakthrough therapy designation for lead candidate EFX for the treatment of MASH
